Compare Quest Diagnostics Inc (DGX) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Select Medical Holdings Corporation — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Quest Diagnostics Inc is far larger — about 11.1× Select Medical Holdings Corporation's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | SEM | |
|---|---|---|
Market Cap | $22.80B | $2.05B |
Sector | Health | Health |
52-Week High | $216.02 | $16.66 |
52-Week Low | $166.42 | $11.77 |
Enterprise Value | $28.82B | $5.01B |
Dividend Yield | 1.67% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Select Medical Holdings (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. announced on June 30, 2026. The stock shows mixed signals with a bullish overall technical outlook but bearish moving averages, while fundamentals indicate modest profitability with a net income margin of 2.42% and a P/E ratio of 15.43. Recent earnings have been inconsistent, with Q1 2026 missing expectations.
The acquisition at $16.50 per share caps near-term upside, with legal investigations into board fiduciary duties posing reputational risks. Analyst sentiment is neutral with a 57.15% hold rating, reflecting uncertainty post-buyout. Investors face limited growth prospects amid stable revenues and margin pressures, emphasizing caution in the current holding pattern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
